Big Pharma China Roundup: Merck Soars, Novartis Sees No Slowdown
This article was originally published in PharmAsia News
Executive Summary
The third quarter proves to be upbeat for big pharma firms in China, with average growth accelerating to 18% compared to 10% in the last quarter. Part 1.